Literature DB >> 9817919

Evidence for furin-type activity-mediated C-terminal processing of profibrillin-1 and interference in the processing by certain mutations.

L Lönnqvist1, D Reinhardt, L Sakai, L Peltonen.   

Abstract

Fibrillin-1 is a major component of the 10 nm microfibrils of the extracellular matrix (ECM). It is synthesized as an approximately 350 kDa precursor molecule, profibrillin-1, which is proteolytically processed into its biologically active approximately 320 kDa form. Furin, a calcium-dependent endoprotease of the subtilisin family, which is known to be the processing enzyme for a variety of proproteins, is believed to be responsible for the N-terminal proteolytic cleavage of profibrillin-1. In this article we provide several lines of evidence that the C-terminal trimming of profibrillin-1 also occurs via a furin-type activity. Edman degradation of a small recombinant C-terminal subdomain of fibrillin-1 revealed complete processing of the peptide immediately after the tribasic recognition sequence (R-X-K/R-R) for furin. In vitro expression experiments using another recombinant construct consisting of the C-terminal half of fibrillin-1 indicated that disruption of the putative recognition sequence for furin by site-directed mutagenesis drastically impairs proteolytic processing of the propeptide. In addition, our results suggest that the N-terminal half of fibrillin-1 is necessary for its incorporation into the ECM.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817919     DOI: 10.1093/hmg/7.13.2039

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  Fibrillin and the eye.

Authors:  J L Ashworth; C M Kielty; D McLeod
Journal:  Br J Ophthalmol       Date:  2000-11       Impact factor: 4.638

2.  Endoproteolytic processing of integrin pro-alpha subunits involves the redundant function of furin and proprotein convertase (PC) 5A, but not paired basic amino acid converting enzyme (PACE) 4, PC5B or PC7.

Authors:  J C Lissitzky; J Luis; J S Munzer; S Benjannet; F Parat; M Chrétien; J Marvaldi; N G Seidah
Journal:  Biochem J       Date:  2000-02-15       Impact factor: 3.857

3.  Profibrillin-1 maturation by human dermal fibroblasts: proteolytic processing and molecular chaperones.

Authors:  Debra D Wallis; Elizabeth A Putnam; Jill S Cretoiu; Sonya G Carmical; Shi-Nian Cao; Gary Thomas; Dianna M Milewicz
Journal:  J Cell Biochem       Date:  2003-10-15       Impact factor: 4.429

4.  Fibrillin-containing microfibrils are key signal relay stations for cell function.

Authors:  Karina A Zeyer; Dieter P Reinhardt
Journal:  J Cell Commun Signal       Date:  2015-10-08       Impact factor: 5.782

Review 5.  The molecular genetics of Marfan syndrome and related microfibrillopathies.

Authors:  P N Robinson; M Godfrey
Journal:  J Med Genet       Date:  2000-01       Impact factor: 6.318

6.  Placensin is a glucogenic hormone secreted by human placenta.

Authors:  Yiping Yu; Jia-Huan He; Lin-Li Hu; Lin-Lin Jiang; Lanlan Fang; Gui-Dong Yao; Si-Jia Wang; Qingling Yang; Yanjie Guo; Lin Liu; Trisha Shang; Yorino Sato; Kazuhiro Kawamura; Aaron Jw Hsueh; Ying-Pu Sun
Journal:  EMBO Rep       Date:  2020-04-24       Impact factor: 8.807

7.  Inactivation of bone morphogenetic protein 1 (Bmp1) and tolloid-like 1 (Tll1) in cells expressing type I collagen leads to dental and periodontal defects in mice.

Authors:  Hua Zhang; Priyam Jani; Tian Liang; Yongbo Lu; Chunlin Qin
Journal:  J Mol Histol       Date:  2016-12-20       Impact factor: 2.611

8.  Asprosin, a Fasting-Induced Glucogenic Protein Hormone.

Authors:  Chase Romere; Clemens Duerrschmid; Juan Bournat; Petra Constable; Mahim Jain; Fan Xia; Pradip K Saha; Maria Del Solar; Bokai Zhu; Brian York; Poonam Sarkar; David A Rendon; M Waleed Gaber; Scott A LeMaire; Joseph S Coselli; Dianna M Milewicz; V Reid Sutton; Nancy F Butte; David D Moore; Atul R Chopra
Journal:  Cell       Date:  2016-04-14       Impact factor: 41.582

Review 9.  The molecular genetics of Marfan syndrome and related disorders.

Authors:  P N Robinson; E Arteaga-Solis; C Baldock; G Collod-Béroud; P Booms; A De Paepe; H C Dietz; G Guo; P A Handford; D P Judge; C M Kielty; B Loeys; D M Milewicz; A Ney; F Ramirez; D P Reinhardt; K Tiedemann; P Whiteman; M Godfrey
Journal:  J Med Genet       Date:  2006-03-29       Impact factor: 6.318

Review 10.  Energy Regulation Mechanism and Therapeutic Potential of Asprosin.

Authors:  Jennifer G Hoffmann; Wei Xie; Atul R Chopra
Journal:  Diabetes       Date:  2020-04       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.